Cargando…
Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer
Nearly all men with prostate cancer treated with androgen receptor (AR) signaling inhibitors (ARSIs) develop resistance via diverse mechanisms including constitutive activation of the AR pathway, driven by AR genomic structural alterations, expression of AR splice variants (AR-Vs), or loss of AR dep...
Autores principales: | Sperger, Jamie M., Emamekhoo, Hamid, McKay, Rana R., Stahlfeld, Charlotte N., Singh, Anupama, Chen, Xinyi E., Kwak, Lucia, Gilsdorf, Cole S., Wolfe, Serena K., Wei, Xiao X., Silver, Rebecca, Zhang, Zhenwei, Morris, Michael J., Bubley, Glenn, Feng, Felix Y., Scher, Howard I., Rathkopf, Dana, Dehm, Scott M., Choueiri, Toni K., Halabi, Susan, Armstrong, Andrew J., Wyatt, Alexander W., Taplin, Mary-Ellen, Zhao, Shuang G., Lang, Joshua M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425833/ https://www.ncbi.nlm.nih.gov/pubmed/34197212 http://dx.doi.org/10.1200/JCO.21.00169 |
Ejemplares similares
-
A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer
por: Zhao, Shuang G., et al.
Publicado: (2022) -
Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma
por: Bade, Rory M., et al.
Publicado: (2021) -
SEEMLIS: a flexible semi-automated method for enrichment of methylated DNA from low-input samples
por: Rodems, Tamara S., et al.
Publicado: (2022) -
Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial
por: McKay, Rana, et al.
Publicado: (2019) -
Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer
por: Han, G. Celine, et al.
Publicado: (2017)